Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

November 30, 2011

Conditions
Solid TumorsAdvanced CancerCancerNeoplasms
Interventions
DRUG

rigosertib sodium

Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.

Trial Locations (1)

10461

Albert Einstein Cancer Center, The Bronx

All Listed Sponsors
lead

Traws Pharma, Inc.

INDUSTRY

NCT01538563 - Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter